
    
      This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160; a
      half-life extended (HLE) bispecific T-cell engager (BiTEÂ®) antibody construct, alone and in
      combination with pembrolizumab in subjects with metastatic castration-resistant prostate
      cancer.
    
  